Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

ttings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. Consistent with the labeling for metformin alone, JANUMET is contraindicated in patients with renal disease, renal dysfunction, or abnormal creatinine clearance; and acute or chronic metabolic acidosis, including diabetic ketoacidosis. JANUMET should not be used in patients with type 1 diabetes. Consistent with the labeling for metformin alone, the labeling for JANUMET contains a boxed warning for lactic acidosis, a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment.

Investigational use of JANUVIA and metformin as initial combination therapy led to improvement in markers of beta cell function in patients with type 2 diabetes (0533-P; Study #036)

In this investigational study, the effects of JANUVIA and metformin on beta cell function were examined in patients with type 2 diabetes who participated in a 24-week, placebo-controlled study in which 1,091 patients were randomized to one of six treatments: JANUVIA 50 mg/metformin 1000 mg twice daily (n=182); JANUVIA 50 mg/metformin 500 mg twice daily (n=190); metformin 1000 mg twice daily (n=182); metformin 500 mg twice daily (n=182); JANUVIA 100 mg once-daily (n=179); or placebo (n=176). Of these, a subset of 500 patients underwent frequently sampled meal tolerance tests. Beta cell function was measured using a computer model based evaluation. Parameters of beta cell function from this model allowed for the estimation of the insulin secretion r
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:12/24/2014)...   The issue: ... confirmed it contains two undeclared amphetamine-like drug substances that ... Empire Health Distribution of Terrebonne, Quebec ... Canada .  Jetfuel Superburn is promoted ... increased energy. What consumers should do ...
(Date:12/24/2014)... -- Kinex Pharmaceuticals announced today that the first patient ... Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, ... inhibitory activity against a broad panel of brain tumor ... (T98G), the most widely used chemotherapy for the treatment ... model, KX2-361 consistently clears brain tumors after 4 weeks ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... Israel, December 20, 2011 During its meeting ... Governors of the Israel-U.S. Binational Industrial Research and Development ... new projects between Israeli and American companies. In addition to ... funding, boosting the total value of all projects to $22 ...
... a medical device company based in Worcester, MA developing ... Company,s $6 M Series B Preferred Stock offering closed ... been catalyzed by our technical progress and recent additions ... Scientific Advisory Board," explained Arthur Combs, Grove,s CEO. ...
Cached Medicine Technology:BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 2BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 3Grove Instruments Inc. Closes $6 M Series B Financing 2Grove Instruments Inc. Closes $6 M Series B Financing 3
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... even mild asthma among young inner-city children appears to be ... after diagnosis is a wise move as a hedge against ... according to a study from the Johns Hopkins Childrens Center. ... months after diagnosis, but six months may be too long ...
... Hopkins have evidence to explain why the supposedly natural act ... for life-threatening heart failure. , In a study ... (AHA) annual Scientific Sessions in Orlando, Fla., the Hopkins team ... pumping function to assess minute changes in the hearts of ...
... to do more to erase racial disparities, study suggests , ... pressure among heart failure patients vary widely by race and ... the Medical University of South Carolina, Mt. Pleasant, noted that ... but experts know little about actual rates of treatment and ...
... at AHA, including one from the Framingham Heart Study,link PAT ... ... ORLANDO, Fla., Nov. 4 Itamar Medical announced,confirmation of ... confirmation of PAT technology, Itamar Medical will now,promote clinical use ...
... increase the rate of coronary reperfusion (restoring blood flow ... the quality of care these patients received, according to ... coincide with its release at the American Heart Associations ... November 28 print issue of JAMA. , ST-segment ...
... Six Percent of Patients Discontinued Combination Therapy ... 4 New data released today,showed that ... proprietary extended-release niacin, Niaspan(R), and,simvastatin met its ... cholesterol minus HDL), while demonstrating improvements,on other ...
Cached Medicine News:Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2Health News:Statewide program helps improve quality of care for heart attack 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 3Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 4Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 5
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
... Aaron manufactures two groups of flexible ... sterile and non-sterile in three different sizes ... flexible shaft portion of the light). These ... additional light is needed., ,The second ...
... toggle switches at off (center position) , ... pulses/10 s) , Tetanus: 50 Hz (50 pulses/s) ... (4 pulses/2 s); repeat (4 pulses/2 s; repeats ... 0-70 mA(HI range) 0-6.0mA (LO range) , Stimulus ...
... Operation: , Standby: A standby switch maintains power ... Twitch: 1 s (1 pulse/s) , Tetanus: ... pulses/2 s) , Output Current: Adjustable from 0-70 ... pulses (200-us duration) , Indicators: Battery LED (green) ...
Medicine Products: